Korean Circ J.  2024 Jul;54(7):407-408. 10.4070/kcj.2024.0170.

What Is a Balanced Way of Anticoagulation for Efficacy and Safety in High-Risk Elderly Patients With Atrial Fibrillation?

• Kim D

• KMID: 2557980
• DOI: http://doi.org/10.4070/kcj.2024.0170

Reference

1. Kim D, Yang PS, Jang E, et al. 10-Year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018; 202:20–26. PMID: 29802976.

2. Kim D, Yang PS, Joung B. Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J. 2022; 52:496–512. PMID: 35790494.

3. Kim M, Kim J, Kim JB, et al. Association of gender with clinical outcomes in a contemporary cohort of patients with atrial fibrillation receiving oral anticoagulants. Korean Circ J. 2022; 52:593–603. PMID: 35656931.

4. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. 2018; 48:1033–1080. PMID: 30403013.

5. Kim D, Yang PS, Sung JH, et al. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. Stroke. 2022; 53:1873–1882. PMID: 35109686.

6. Sabbag A, Yao X, Siontis KC, Noseworthy PA. Anticoagulation for stroke prevention in older adults with atrial fibrillation and comorbidity: current evidence and treatment challenges. Korean Circ J. 2018; 48:873–889. PMID: 30238705.

7. Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020; 383:1735–1745. PMID: 32865374.

8. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017; 69:2779–2790. PMID: 28595692.

9. Chan YH, Chao TF, Chen SW, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023; 9:681–691. PMID: 37580139.

10. Kim JY, Kim J, Park SJ, et al. Optimal dose of edoxaban for very elderly atrial fibrillation patients at high risk of bleeding: the LEDIOS registry. Korean Circ J. 2024; 54:398–406. PMID: 38859644.